COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive.

29,084 Articles (21,556 medRxiv, 7,528 bioRxiv)

Most recent first Previous |  Page 2905: Articles 29041-29050  | Next

Early evaluation of the Wuhan City travel restrictions in response to the 2019 novel coronavirus outbreak
Tian, H., Li, Y., Liu, Y., Kraemer, M. U. G., Chen, B., Cai, J., Li, B., Xu, B., Yang, Q., Yang, P., Cui, Y., Song, Y., Zheng, P., Wang, Q., Bjornstad, O. N., Yang, R., Pybus, O., Grenfell, B., Dye, C.
10.1101/2020.01.30.20019844 — Posted: 2020-02-02 Discussion: Offsite
Early dynamics of transmission and control of 2019-nCoV: a mathematical modelling study
Kucharski, A. J., Russell, T. W., Diamond, C., CMMID nCoV working group, , Funk, S., Eggo, R. M.
10.1101/2020.01.31.20019901 — Posted: 2020-02-02 Discussion: Onsite
Effectiveness of airport screening at detecting travellers infected with 2019-nCoV
Quilty, B., Clifford, S., Flasche, S., Eggo, R. M.
10.1101/2020.01.31.20019265 — Posted: 2020-02-02
Highly Distinguished Amino Acid Sequences of 2019-nCoV (Wuhan Coronavirus)
Beal, J., Mitchell, T., Wyschogrod, D., Manthey, J., Clore, A.
10.1101/2020.01.31.929497 — Posted: 2020-02-02 Discussion: Onsite
Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
Lei, C., Fu, W., Qian, K., Li, T., Zhang, S., Ding, M., Hu, S.
10.1101/2020.02.01.929976 — Posted: 2020-02-02 Discussion: Onsite
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model
Beck, B. R., Shin, B., Choi, Y., Park, S., Kang, K.
10.1101/2020.01.31.929547 — Posted: 2020-02-02 Discussion: Onsite
Genome Detective Coronavirus Typing Tool for rapid identification and characterization of novel coronavirus genomes
Cleemput, S., Dumon, W., Fonseca, V., Abdool Karim, W., Giovanetti, M., Alcantara, L. C. J., Deforche, K., de Oliveira, T.
10.1101/2020.01.31.928796 — Posted: 2020-02-02
Nucleotide Analogues as Inhibitors of Viral Polymerases
Ju, J., Kumar, S., Li, X., Jockusch, S., Russo, J. J.
10.1101/2020.01.30.927574 — Posted: 2020-01-31
The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
Hoffmann, M., Kleine-Weber, H., Krueger, N., Mueller, M. A., Drosten, C., Poehlmann, S.
10.1101/2020.01.31.929042 — Posted: 2020-01-31 Discussion: Onsite
The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes
Zhang, H., Kang, Z., Gong, H., Xu, D., Wang, J., Li, Z., Cui, X., Xiao, J., Meng, T., Zhou, W., Liu, J., Xu, H.
10.1101/2020.01.30.927806 — Posted: 2020-01-31 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).